1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Bullous Pemphigoid - Pipeline Review, H2 2013

Bullous Pemphigoid - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 43 pages

Bullous Pemphigoid - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Bullous Pemphigoid - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bullous Pemphigoid, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bullous Pemphigoid. Bullous Pemphigoid - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bullous Pemphigoid.
- A review of the Bullous Pemphigoid products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bullous Pemphigoid pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bullous Pemphigoid.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bullous Pemphigoid pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Bullous Pemphigoid - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bullous Pemphigoid Overview 6
Therapeutics Development 7
Pipeline Products for Bullous Pemphigoid - Overview 7
Pipeline Products for Bullous Pemphigoid - Comparative Analysis 8
Bullous Pemphigoid - Therapeutics under Development by Companies 9
Bullous Pemphigoid - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Bullous Pemphigoid - Products under Development by Companies 13
Bullous Pemphigoid - Companies Involved in Therapeutics Development 14
Novartis AG 14
iCo Therapeutics Inc. 15
Nihon Pharmaceutical Industry Co., Ltd. 16
vida therapeutics inc. 17
Bullous Pemphigoid - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Assessment by Therapeutic Class 27
Drug Profiles 30
NPB-01 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
QGE-031 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
bertilimumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
V-2248 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Drug For Autoimmune Disorders - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Bullous Pemphigoid - Recent Pipeline Updates 39
Bullous Pemphigoid - Dormant Projects 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43



List of Tables

Number of Products under Development for Bullous Pemphigoid, H2 2013 7
Number of Products under Development for Bullous Pemphigoid - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Late Stage Development, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Bullous Pemphigoid - Pipeline by Novartis AG, H2 2013 14
Bullous Pemphigoid - Pipeline by iCo Therapeutics Inc., H2 2013 15
Bullous Pemphigoid - Pipeline by Nihon Pharmaceutical Industry Co., Ltd., H2 2013 16
Bullous Pemphigoid - Pipeline by vida therapeutics inc., H2 2013 17
Assessment by Monotherapy Products, H2 2013 18
Number of Products by Stage and Target, H2 2013 20
Number of Products by Stage and Mechanism of Action, H2 2013 22
Number of Products by Stage and Route of Administration, H2 2013 24
Number of Products by Stage and Molecule Type, H2 2013 26
Number of Products by Stage and Therapeutic Class, H2 2013 29
Bullous Pemphigoid Therapeutics - Recent Pipeline Updates, H2 2013 39
Bullous Pemphigoid - Dormant Projects, H2 2013 41



List of Figures

Number of Products under Development for Bullous Pemphigoid, H2 2013 7
Number of Products under Development for Bullous Pemphigoid - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 18
Number of Products by Top 10 Target, H2 2013 19
Number of Products by Stage and Top 10 Target, H2 2013 20
Number of Products by Top 10 Mechanism of Action, H2 2013 21
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 22
Number of Products by Top 10 Route of Administration, H2 2013 23
Number of Products by Stage and Top 10 Route of Administration, H2 2013 24
Number of Products by Top 10 Molecule Type, H2 2013 25
Number of Products by Stage and Top 10 Molecule Type, H2 2013 26
Number of Products by Top 10 Therapeutic Class, H2 2013 27
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 28



Companies Mentioned

Novartis AG
iCo Therapeutics Inc.
Nihon Pharmaceutical Industry Co., Ltd.
vida therapeutics inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Nuclear Factor Erythroid 2 Related ...

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen ...

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016’, ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.